(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

Quetiapine efficacy for treatment of psychosis in Parkinson's disease is questionable

What is it about?

We systematically identified and examined data from seven randomized controlled trials on quetiapine for treatment of psychosis in patients with parkinsonism. The mean daily dose was 103 mg per day. In terms of side effects, quetiapine was well tolerated and not associated with significant worsening of motor function. However, treatment-emergent somnolence was a common reason for study discontinuation. In terms of efficacy, quetiapine failed to demonstrate significant improvement of psychotic symptoms in patients with parkinsonism compared to placebo or clozapine.

Why is it important?

The best available evidence from randomized controlled trials indicates that quetiapine is not more effective than placebo for hallucinations and psychosis in patients with Parkinson's disease

Read more on Kudos…
The following have contributed to this page:
Jack Chen and Jack Chen
' ,"url"));